Brepocitinib Overview & RVT-3101 Update
Roivant Pipeline
VTAMA / Psoriasis | Dermavant
(tapinarof) cream 1%
VTAMA/Atopic Dermatitis | Dermavant
(tapinarof) cream 1%
RVT-3101 Ulcerative Colitis | New Vant
RVT-3101 Crohn's Diseases | New Vant
BREPOCITINIB Dermatomyositis | Priovant
BREPOCITINIB Systemic Lupus Erythematosus | Priovant
BREPOCITINIB Other Indications | Priovant
A
BATOCLIMAB Myasthenia Gravis | Immunovant
Y
BATOCLIMAB Thyroid Eye Disease | Immunovant
BATOCLIMAB Chronic Inflammatory Demyelinating Polyneuropathy | Immunovant
Y
BATOCLIMAB Graves' Disease | Immunovant
A
BATOCLIMAB Warm Autoimmune Hemolytic Anemia | Immunovant
Y
IMVT-1402 Numerous Indications | Immunovant
n NAMILUMAB Sarcoidosis | Kinevant
RVT-2001 Transfusion-Dependent Anemia in Patients with Lower-Risk MDS | Hemavant
roivant
Pipeline reflects both ongoing clinical trials and expected upcoming trials. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis.
Modality
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Topical
Topical
Biologic
Biologic
Small Molecule
Small Molecule
Small Molecule
Biologic
Biologic
Biologic
Biologic
Biologic
Biologic
Biologic
Small Molecule
Represents registrational or potentially
registrational trials
For investor audiences only
5View entire presentation